CGMPs For PET Drugs Should Be Performance-Based, Not Prescriptive - ICP
This article was originally published in The Gray Sheet
Executive Summary
Current good manufacturing practices enforced by FDA for manufacturers of positron emission tomography (PET) radiopharmaceuticals should be performance-based rather than prescriptive, representatives of the Institute for Clinical PET maintain.